FDA delays Moderna for adolescents to review rare side effect
FDA delays Moderna for adolescents to review rare side effect The Food and Drug Administration is delaying a decision on authorizing Moderna Inc.’s MRNA -1.69% COVID-19 vaccine for adolescents to assess whether the shot may lead to heightened risk of a rare inflammatory heart condition, according to people familiar with the matter.